BCMA-directed CAR-T cell therapy induces durable drug-free remission in refractory primary immune thrombocytopenia.

Authors

Jinhui Shu, Min Xu, Peiru Li, Wei Xie, Lin Liu, Hongjian Li, James B Bussel, Yu Hu, Heng Mei

Published in

Blood. Jul 24, 2026. Epub Jul 24, 2026.

Abstract

This first clinical evaluation of BCMA CAR-T cell therapy in four patients with refractory primary ITP demonstrated manageable safety, rapid and sustained platelet recovery, and durable drug-free complete remission lasting up to 15 months, supporting further evaluation in larger studies.

PMID:
42498681
Bibliographic data and abstract were imported from PubMed on 25 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.